Implementation of the Inflation Reduction Act of 2022;
Help Copays Act (HR 830 / S. 1375);
Orphan Cures Act (HR 5539 / S. 3131);
National Plan to End Parkinson's Act (HR 2365 / S. 1064);
Protect Rare Act (HR 6094);
The Creating Hope Act (HR 7384).
Implementation of the Inflation Reduction Act of 2022;
Issues related to protecting patient access to medicines in Medicare;
Issues related to access to medicines for Parkinson's disease patients;
Issues Related to Antipsychotic use in Medicaid (HR 4096);
Orphan Cures Act (HR 5539 / S. 3131);
National Plan to End Parkinson's Act (HR 2365 / S. 1064);
Protect Rare Act (HR 6094);
EPIC Act (HR 7174).
Duration: October 27, 2020
to
present
General Issues: Health Issues , Medicare/Medicaid , Budget/Appropriations , Defense
Spending: about $3,180,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2020: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, ACADIA PHARMACEUTICALS had in-house lobbyists. The report was filed on April 16.
Original Filing: 301551257.xml
Lobbying Issues
Implementation of the Inflation Reduction Act of 2022;
Help Copays Act (HR 830 / S. 1375);
Orphan Cures Act (HR 5539 / S. 3131);
National Plan to End Parkinson's Act (HR 2365 / S. 1064);
Protect Rare Act (HR 6094);
The Creating Hope Act (HR 7384).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of the Inflation Reduction Act of 2022;
Issues related to protecting patient access to medicines in Medicare;
Issues related to access to medicines for Parkinson's disease patients;
Issues Related to Antipsychotic use in Medicaid (HR 4096);
Orphan Cures Act (HR 5539 / S. 3131);
National Plan to End Parkinson's Act (HR 2365 / S. 1064);
Protect Rare Act (HR 6094);
EPIC Act (HR 7174).
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, ACADIA PHARMACEUTICALS had in-house lobbyists. The report was filed on Jan. 19.
Original Filing: 301531388.xml
Lobbying Issues
Implementation of the Inflation Reduction Act of 2022;
Help Copays Act (HR 830 / S. 1375);
Orphan Cures Act (HR 5539);
Issues related to rare disease research incentives;
National Plan to End Parkinson's Act (HR 2365 / S. 1064);
Protect Rare Act (HR 6094).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of the Inflation Reduction Act of 2022;
Six Protected Classes: Issues related to protecting patient access to medicines in Medicare;
Nursing Home Quality: Issues related to access to medicines for Parkinson's disease patients;
HR 4096 - Issues Related to Antipsychotic use in Medicaid;
HR 5539 - Orphan Cures Act;
HR 2365 / S. 1064 - National Plan to End Parkinson's Act;
HR 6094 - Protect Rare Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, ACADIA PHARMACEUTICALS had in-house lobbyists. The report was filed on Oct. 18, 2023.
Original Filing: 301503456.xml
Lobbying Issues
Drug Pricing: Implementation of the Inflation Reduction Act of 2022;
Help Copays Act (H.R. 830 / S. 1375);
Orphan Cures Act (H.R. 5539);
Issues related to rare disease research incentives;
National Plan to End Parkinson's Act (H.R. 2365 / S. 1064).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug Pricing: Implementation of the Inflation Reduction Act of 2022;
Protected Classes: Issues related to protecting patient access to medicines in Medicare;
Nursing Home Quality: Issues related to medicines in nursing homes;
HR 4096 - Issues Related to Antipsychotic use in Medicaid;
HR 5539 - Orphan Cures Act;
HR 2365 / S. 1064 - National Plan to End Parkinson's Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, ACADIA PHARMACEUTICALS had in-house lobbyists. The report was filed on July 20, 2023.
Original Filing: 301485896.xml
Lobbying Issues
Drug Pricing: Implementation of the Inflation Reduction Act of 2022;
Help Copays Act (H.R. 830).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug Pricing: Implementation of the Inflation Reduction Act of 2022;
Six Protected Classes: Issues related to protecting patient access to medicines in Medicare;
Nursing Home Quality: Issues related to medicines in nursing homes;
HR 4096; Issues Related to Antipsychotic use in Medicaid.
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, ACADIA PHARMACEUTICALS had in-house lobbyists. The report was filed on April 19, 2023.
Original Filing: 301458654.xml
Lobbying Issues
Drug Pricing: Implementation of the Inflation Reduction Act of 2022.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug Pricing: Implementation of the Inflation Reduction Act of 2022;
Six Protected Classes: Issues related to protecting patient access to medicines in Medicare;
Nursing Home Quality: Issues related to medicines in nursing homes.
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, ACADIA PHARMACEUTICALS had in-house lobbyists. The report was filed on Jan. 19, 2023.
Original Filing: 301433672.xml
Lobbying Issues
Drug pricing issues: H.R. 5376, Inflation Reduction Act of 2022;
Neurology Research: S. 4661 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023;
Rett Syndrome Research: H.R. 8236 Department of Defense Appropriations Act, 2023;
Parkinson's Plan: S. 4851, National Plan to End Parkinsons Act;
Consolidated Appropriations Act, 2023: H.R.216
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug Pricing Issues: H.R. 5376, Inflation Reduction Act of 2022;
Nursing Home Quality: S. 4659, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023;
Parkinson's Plan: S. 4851, National Plan to End Parkinsons Act;
Six Protected Classes resolution: H. Res. 1390, Expressing support for the protection of Medicare part D's six protected classes
Agencies Lobbied
U.S. Senate
Lobbying Issues
Nursing Home Quality: S. 4659 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023;
Neurology Research: S. 4661 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023;
Rett Syndrome Research: H.R. 8236, Department of Defense Appropriations Act, 2023;
Consolidated Appropriations Act, 2023: H.R.216
Agencies Lobbied
U.S. Senate
Lobbying Issues
Rett Syndrome Research: H.R. 8236 Department of Defense Appropriations Act, 2023
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
ACADIA PHARMACEUTICALS amended a lobbying report for in-house lobbying in Q42022 on Jan. 19, 2023
Original Filing: 301433776.xml
Lobbying Issues
Drug pricing issues: H.R. 5376, Inflation Reduction Act of 2022;
Neurology Research: S. 4661 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023;
Rett Syndrome Research: H.R. 8236 Department of Defense Appropriations Act, 2023;
Parkinson's Plan: S. 4851, National Plan to End Parkinsons Act;
H.R.2617 - Consolidated Appropriations Act, 2023, 117th Congress (2021-2022)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug Pricing Issues: H.R. 5376, Inflation Reduction Act of 2022;
Nursing Home Quality: S. 4659, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023;
Parkinson's Plan: S. 4851, National Plan to End Parkinsons Act;
Six Protected Classes resolution: H. Res. 1390, Expressing support for the protection of Medicare part D's six protected classes
Agencies Lobbied
U.S. Senate
Lobbying Issues
Nursing Home Quality: S. 4659 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023;
Neurology Research: S. 4661 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023;
Rett Syndrome Research: H.R. 8236, Department of Defense Appropriations Act, 2023;
H.R.2617 - Consolidated Appropriations Act, 2023, 117th Congress (2021-2022)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Rett Syndrome Research: H.R. 8236 Department of Defense Appropriations Act, 2023
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, ACADIA PHARMACEUTICALS had in-house lobbyists. The report was filed on Oct. 19, 2022.
Original Filing: 301412261.xml
Lobbying Issues
Drug pricing issues: H.R. 5376, Inflation Reduction Act of 2022;
Neurology Research: S. 4661 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023;
Rett Syndrome Research: H.R. 8236 Department of Defense Appropriations Act, 2023;
Parkinson's Plan: S. 4851, National Plan to End Parkinsons Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug Pricing Issues: H.R. 5376, Inflation Reduction Act of 2022;
Nursing Home Quality: S. 4659, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023;
Parkinson's Plan: S. 4851, National Plan to End Parkinsons Act;
Six Protected Classes resolution: H. Res. 1390, Expressing support for the protection of Medicare part D's six protected classes
Agencies Lobbied
U.S. Senate
Lobbying Issues
Nursing Home Quality: S. 4659 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023;
Neurology Research: S. 4661 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023;
Rett Syndrome Research: H.R. 8236, Department of Defense Appropriations Act, 2023
Agencies Lobbied
U.S. Senate
Lobbying Issues
Rett Syndrome Research: H.R. 8236 Department of Defense Appropriations Act, 2023
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, ACADIA PHARMACEUTICALS had in-house lobbyists. The report was filed on July 20, 2022.
Original Filing: 301390314.xml
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare reform; Telehealth issues
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In 1A, ACADIA PHARMACEUTICALS did no lobbying for itself. The report was filed on Aug. 18, 2022.
Original Filing: 301399072.xml
1st Quarter, 2022
In Q1, ACADIA PHARMACEUTICALS did no lobbying for itself. The report was filed on April 19, 2022.
Original Filing: 301361899.xml
4th Quarter, 2021
In Q4, ACADIA PHARMACEUTICALS had in-house lobbyists. The report was filed on Jan. 20, 2022.
Original Filing: 301337411.xml
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare reform; Telehealth issues
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, ACADIA PHARMACEUTICALS had in-house lobbyists. The report was filed on Oct. 19, 2021.
Original Filing: 301306784.xml
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare reform; Telehealth issues
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, ACADIA PHARMACEUTICALS had in-house lobbyists. The report was filed on July 19, 2021.
Original Filing: 301282715.xml
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare reform; Telehealth issues
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, ACADIA PHARMACEUTICALS had in-house lobbyists. The report was filed on April 20, 2021.
Original Filing: 301267130.xml
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare reform; Telehealth issues
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, ACADIA PHARMACEUTICALS had in-house lobbyists. The report was filed on Jan. 20, 2021.
Original Filing: 301240604.xml
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare reform; Telehealth issues
Agencies Lobbied
U.S. Senate
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...